Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.23
+0.01 (0.19%)
At close: Nov 20, 2024, 4:00 PM
5.31
+0.08 (1.53%)
Pre-market: Nov 21, 2024, 4:04 AM EST

Amylyx Pharmaceuticals Revenue

Amylyx Pharmaceuticals had revenue of $416.00K in the quarter ending September 30, 2024, a decrease of -99.59%. This brings the company's revenue in the last twelve months to $196.49M, down -33.22% year-over-year. In the year 2023, Amylyx Pharmaceuticals had annual revenue of $380.79M with 1,612.94% growth.

Revenue (ttm)
$196.49M
Revenue Growth
-33.22%
P/S Ratio
1.81
Revenue / Employee
$511,680
Employees
384
Market Cap
356.07M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023380.79M358.56M1,612.94%
Dec 31, 202222.23M21.95M7,700.00%
Dec 31, 2021285.00K-365.00K-56.15%
Dec 31, 2020650.00K-776.00K-54.42%
Dec 31, 20191.43M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
ZimVie 451.29M
Tactile Systems Technology 285.05M
AirSculpt Technologies 188.78M
Valneva SE 176.82M
Akebia Therapeutics 169.88M
ProQR Therapeutics 20.51M
4D Molecular Therapeutics 17.00K
Q32 Bio -14.66M
Revenue Rankings